Back to all studiesRecruitingNCT05656469
Pharmacogenetic-guided medication versus usual dosing for mental health conditions
About this title
Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders
Read the official source — NCT05656469Interventional studyAges 16–70Multiple countriesAnxiety
The study in practiceUnderstand this study
Who could participate?
Listed age limits: 16 years to 70 years.
- Compensation
- Payment and expense reimbursement have not been verified.
What to know before participating
A point to clarifyThis summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Study clarityThings to check before joining
Study start dateStarted: February 23, 2023
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 2,500
- Sponsor
- Parnassia Groep
- Sponsor type
- Unknown or unclear
- Study type
- Other
- Intervention type
- OTHER
- Study phase
- Not clearly listed
- Locations
- United States, United Kingdom, Germany, ...
- Age range
- From 16 Years to 70 Years
- Official registry ID
- NCT05656469
- Official title
Show the full official title
A New Intervention for Implementation of Pharmacogenetics in Psychiatry
Questions about this study?
The HopeStage team will email you.
Syracuse, United States · Bonn, Germany · München, Germany
6 more locations
- Amsterdam, Netherlands
- Maastricht, Netherlands
- Cluj-Napoca, Romania
- Belgrade, Serbia
- Barcelona, Spain
- London, United Kingdom
A listed location does not confirm current availability.
FAQQuestions about this study
Who is behind this study?
The study sponsor is Parnassia Groep.
Who can participate?
Listed age limits: 16 years to 70 years.
Is this study still recruiting?
The registry lists this study as recruiting.
Explore other studiesWant to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me